Drug Profile


Alternative Names: JO 1017

Latest Information Update: 15 Jul 1999

Price : $50

At a glance

  • Originator Jouveinal
  • Class Antidepressants; Propanolamines; Small molecules
  • Mechanism of Action Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Major depressive disorder

Most Recent Events

  • 15 Jul 1999 No-Development-Reported for Depression in France (PO)
  • 15 Jul 1999 No-Development-Reported for Depression in United Kingdom (PO)
  • 15 Aug 1996 Phase-III clinical trials for Depression in United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top